This study includes all the children treated with OK-432 for lymphangioma at our institute. Twenty-nine children treated between 1999 and 2003 are reported for the first time: twelve cases regressed completely, eight cases regressed more than 50% and seven remained unchanged; two cases were lost at follow-up. The outcome was related to the size of the cysts, the larger ones having a better prognosis. The adverse reactions are discussed and the methods of treatment are described in detail. Fifteen children, treated before 1999 and already reported, are reviewed after a long-term follow-up. Four had a recurrence: one regressed spontaneously and three needed further treatment. The other 11 had no complaints. Even considering the risk of recurrence, OK-432 therapy remains our first line therapy for lymphangiomas, avoiding surgery in most cases.
This is a preview of subscription content, log in to check access.
Luzzatto C, Midrio P, Tchaprassian Z, Guglielmi M (2000) Sclerosing treatment of lymphangiomas with OK-432. Arch Dis Child 82(4):316–318CrossRefPubMedGoogle Scholar
Ogita S, Tsuto T, Tokiwa K, Takahashi T (1987) Intracystic injection of OK-432: a new sclerosing therapy for cystic hygroma in children. Br J Surg 74(8):690–691PubMedCrossRefGoogle Scholar
Ruiz E Jr, Valera ET, Verissimo F, Tone LG (2004) OK-432 therapy for lymphangioma in children. J Pediatr (Rio J) 80(2):154–158CrossRefGoogle Scholar
Laranne J, Keski-Nisula L, Rautio R, Rautiainen M, Airaksinen M (2002) OK-432 (Picibanil) therapy for lymphangiomas in children. Eur Arch Otorhinolaryngol 259(5):274–278CrossRefPubMedGoogle Scholar
Claesson G, Kuylenstierna R (2002) OK-432 therapy for lymphatic malformation in 32 patients (28 children). Int J Pediatr Otorhinolaryngol 65(1):1–6CrossRefPubMedGoogle Scholar
Sung MW, Lee DW, Kim DY et al (2001) Sclerotherapy with Picibanil (OK-432) for congenital lymphatic malformation in the head and neck. Laryngoscope 111(8):1430–1433CrossRefPubMedGoogle Scholar
Smith RJ, Burke DK, Sato Y, Poust RI, Kimura K, Bauman NM (1996) OK-432 therapy for Lymphangiomas. Arch Otolaryngol Head Neck Surg 122(11):1195–1199PubMedGoogle Scholar
Banieghbal B, Davies MR (2003) Guidelines for the successful treatment of lymphangioma with OK-432. Eur J Pediatr Surg 13(2):103–107PubMedCrossRefGoogle Scholar
Ogita S,Tsuto T, Nakamura K, Deguchi E, Tokiwa K, Iwai N (1996) OK-432 therapy for lymphangioma in children:why and how does it work? J Pediatr Surg 31(4):477–480CrossRefPubMedGoogle Scholar
Fujino A,Moriya Y, Morikawa Y et al (2003) A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism. J Pediatr Surg 38(12):1806–1809CrossRefPubMedGoogle Scholar
Hall N, Ade-Ajayi N, Brewis C et al (2003) Is intralesional injection of OK-432 effective in the treatment of lymphangioma in children? Surgery 133(3):238–242CrossRefPubMedGoogle Scholar
Kennedy TL,Whitaker M, Pellitteri P, Wood WE (2001) Cystic Hygroma/lymphangioma: a rational approach to management. Laryngoscope 111(11 Pt 1):1929–1937CrossRefPubMedGoogle Scholar